|
This is an index of reports of adverse events (side effects, adverse reactions, etc.) related to Cyclophosphamide. Click on the relevant link below to view a selection of reports according to the event's seriousness level and/or the nature of the side effect / adverse reaction. Or scroll down to view a sample of recent reports further on this page.
Our database includes reports from Jan 2007 to Dec 2007. The information is not vetted and should not be cosidered as verified clinical evidence.
All cases (1384)
Cases resulting in a serious event (1344)
Cases resulting in death (381)
Cases resulting in life threatening events (126)
Cases resulting in hospitalization (659)
Cases resulting in disability (43)
Cases resulting in other serious reactions (539)
Below is a sample of reports where side effects / adverse reactions may be related to Cyclophosphamide. For a complete list and/or a specific selection of reports, please use the links in the index above.
Adverse event in female receiving Cyclophosphamide
Reported by a health professional (non-physician/pharmacist) from United States on 2007-10-31
Patient: female, weighing 72.2 kg (158.8 pounds)
Adverse reactions / side effects: Vomiting, Diarrhoea, Nausea, Chills, Haemolytic Anaemia, Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 250 mg/m2 days 1-3 q 4 wks x 6 months iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-12
Cyclophosphamide
Dosage: 250 mg/m2 days 1-3 q 4 wks x 6 months iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-13
Cyclophosphamide
Dosage: 250 mg/m2 days 1-3 q 4 wks x 6 months iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-14
Fludarabine Phosphate
Dosage: 25 mg/m2 days 1-3 q 4 wks x 6 months iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-12
Fludarabine Phosphate
Dosage: 25 mg/m2 days 1-3 q 4 wks x 6 months iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-13
Fludarabine Phosphate
Dosage: 25 mg/m2 days 1-3 q 4 wks x 6 months iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-14
Adverse event in 7 year old female receiving Cyclophosphamide
Reported by a consumer/non-health professional from Greece on 2007-10-31
Patient: 7 year old female, weighing 25.0 kg (55.0 pounds)
Adverse reactions / side effects: Erythema Infectiosum, Histiocytosis Haematophagic
Adverse event resulted in: death
Suspect drug(s):
Azathioprine
Indication: Diffuse Vasculitis
Start date: 2001-08-01
Cyclophosphamide
Indication: Diffuse Vasculitis
Start date: 2007-04-27
End date: 2007-04-27
Cyclosporine
Indication: Diffuse Vasculitis
Start date: 2007-05-02
End date: 2007-05-04
Etanercept
Indication: Diffuse Vasculitis
Start date: 2001-08-01
Kineret
Indication: Diffuse Vasculitis
Start date: 2006-03-22
End date: 2007-04-20
Methotrexate
Indication: Diffuse Vasculitis
Start date: 2001-08-01
Methylprednisolone
Indication: Diffuse Vasculitis
Start date: 2007-05-03
End date: 2007-05-05
Prednisolone
Administration route: Oral
Indication: Diffuse Vasculitis
Start date: 2001-06-20
End date: 2002-05-15
Other drugs received by patient: Corticosteroid
Adverse event in receiving Cyclophosphamide
Reported by a individual with unspecified qualification from France on 2007-10-31
Patient:
Adverse reactions / side effects: Drug Toxicity
Adverse event resulted in: death
Suspect drug(s):
Alkeran
Dosage: oral
Administration route: Oral
Indication: Multiple Myeloma
Cyclophosphamide
Indication: Stem Cell Transplant
Dexamethasone
Dosage: oral
Administration route: Oral
Indication: Multiple Myeloma
Disodium Clodronate (Formulation Unknown) (Disodium Clodronate)
Dosage: oral
Administration route: Oral
Doxorubicin HCL
Dosage: intravenous infus
Indication: Multiple Myeloma
Granulocyte Col.stim.fact (Formulation Unknown) (Granulocyte Col.stim.
Mesna
Indication: Stem Cell Transplant
Stem Cell Transplant (Formulation Unknown) (Stem Cell Transplant)
Vincristine
Dosage: intravenous infus
Indication: Multiple Myeloma
Adverse event in 70 year old female receiving Cyclophosphamide
Reported by a physician from Germany on 2007-10-31
Patient: 70 year old female
Adverse reactions / side effects: Epstein-Barr Virus Infection, Multi-Organ Failure, Fatigue, Necrosis, Lymphoproliferative Disorder, Lung Infiltration, Disease Progression
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Cyclophosphamide
Everolimus
Fludarabine
Adverse event in receiving Cyclophosphamide
Reported by a individual with unspecified qualification from France on 2007-10-31
Patient:
Adverse reactions / side effects: Drug Toxicity, Cardiac Failure
Adverse event resulted in: death
Suspect drug(s):
Alkeran
Dosage: oral
Administration route: Oral
Indication: Multiple Myeloma
Cyclophosphamide
Indication: Stem Cell Transplant
Dexamethasone
Dosage: oral
Administration route: Oral
Indication: Multiple Myeloma
Disodium Clodronate (Formulation Unknown) (Disodium Clodronate)
Dosage: oral
Administration route: Oral
Doxorubicin Hydrochloride
Dosage: intravenous infus
Indication: Multiple Myeloma
Granulocyte Col.stim.fact (Formulation Unknown) (Granulocyte Col.stim.
Mesna
Indication: Stem Cell Transplant
Stem Cell Transplant (Formulation Unknown) (Stem Cell Transplant)
Indication: Multiple Myeloma
Vincristine
Dosage: intravenous infus
Indication: Multiple Myeloma
Adverse event in 53 year old male receiving Cyclophosphamide
Reported by a physician from Germany on 2007-10-31
Patient: 53 year old male, weighing 100.0 kg (220.0 pounds)
Adverse reactions / side effects: Disseminated Intravascular Coagulation, Hepatic Failure, Continuous Haemodiafiltration, Pulmonary Embolism, Pupils Unequal, Left Ventricular Failure, Erythema, Multi-Organ Failure, Acute Respiratory Distress Syndrome, Thrombocytopenia, Sinusitis, Acute Respiratory Failure, Renal Failure Acute, Tachyarrhythmia, Hypotension, Skin Disorder, Mastoiditis, Haemodialysis, Cardiac Failure, Staphylococcal Infection, Septic Shock, Purulent Discharge
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 1800.00 mg, intravenous
Indication: Plasmacytoma
Start date: 2007-07-02
End date: 2007-07-02
Dexamethasone
Dosage: 40.00 mg, oral
Administration route: Oral
Indication: Plasmacytoma
Start date: 2007-06-02
Velcade
Dosage: 2.60 mg, intravenous
Indication: Plasmacytoma
Start date: 2007-07-02
End date: 2007-07-02
Other drugs received by patient: Dipyrone TAB; Buprenorphine Hydrochloride; Pantoprazole Sodium
Adverse event in 54 year old male receiving Cyclophosphamide
Reported by a individual with unspecified qualification on 2007-10-31
Patient: 54 year old male
Adverse reactions / side effects: Jaundice, Graft Versus Host Disease, Lymphopenia, Anaemia, Pyrexia, Generalised Erythema, Diarrhoea, Circulatory Collapse, Neutropenia, Thrombocytopenia, Septic Shock, Leukopenia
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Cyclophosphamide
Adverse event in receiving Cyclophosphamide
Reported by a health professional (non-physician/pharmacist) from United States on 2007-10-31
Patient: , weighing 93.8 kg (206.4 pounds)
Adverse reactions / side effects: Pneumonia
Adverse event resulted in: hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 250mg/m2 days 1-3 q4wks x 6 mos iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-07-04
Cyclophosphamide
Dosage: 250mg/m2 days 1-3 q4wks x 6 mos iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-07-05
Cyclophosphamide
Dosage: 250mg/m2 days 1-3 q4wks x 6 mos iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-07-06
Fludarabine Phosphate
Dosage: 25mg/m2 days 1-3 q4wks x 6 mos iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-07-04
Fludarabine Phosphate
Dosage: 25mg/m2 days 1-3 q4wks x 6 mos iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-07-05
Fludarabine Phosphate
Dosage: 25mg/m2 days 1-3 q4wks x 6 mos iv
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-07-06
Adverse event in 52 year old female receiving Cyclophosphamide
Reported by a individual with unspecified qualification from United Kingdom on 2007-10-31
Patient: 52 year old female, weighing 54.0 kg (118.8 pounds)
Adverse reactions / side effects: Malaise, Nausea, Drug Interaction
Suspect drug(s):
Cyclizine
Cyclophosphamide
Indication: Lymphoma
Doxorubicin HCL
Indication: Lymphoma
Fludarabine Phosphate
Indication: Chronic Lymphocytic Leukaemia
Granisetron HCL
Dosage: 3 mg qd iv
Indication: Lymphoma
Start date: 2007-08-28
Prednisone TAB
Indication: Lymphoma
Tegretol
Dosage: 400 mg tid po
Administration route: Oral
Indication: Epilepsy
Vincristine
Indication: Lymphoma
Zofran
Dosage: 8 mg tid po
Administration route: Oral
Adverse event in 68 year old male receiving Cyclophosphamide
Reported by a individual with unspecified qualification on 2007-10-31
Patient: 68 year old male
Adverse reactions / side effects: Erythema Infectiosum, Disease Recurrence, Hepatitis Acute, Epstein-Barr Virus Test Positive, Aplasia Pure RED Cell, Lymphoproliferative Disorder
Suspect drug(s):
Campath
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-04-01
End date: 2006-06-01
Cyclophosphamide
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2004-02-01
Fludarabine Phosphate
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2004-02-01
Other drugs received by patient: Immunoglobulins
Adverse event in 4 year old male receiving Cyclophosphamide
Reported by a physician from United States on 2007-10-30
Patient: 4 year old male
Adverse reactions / side effects: Acute Myeloid Leukaemia
Suspect drug(s):
Carboplatin
Indication: Retinoblastoma Unilateral
Cyclophosphamide
Indication: Retinoblastoma Unilateral
Etoposide
Indication: Retinoblastoma Unilateral
Vincristine
Indication: Retinoblastoma Unilateral
Adverse event in male receiving Cyclophosphamide
Reported by a individual with unspecified qualification from United States on 2007-10-30
Patient: male, weighing 76.0 kg (167.2 pounds)
Adverse reactions / side effects: Klebsiella Infection, Culture Urine Positive
Adverse event resulted in: hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 1965 mg
Doxorubicin Hydrochloride
Dosage: 104 mg
Etoposide
Dosage: 520 mg
Prednisone TAB
Dosage: 990 mg
Rituximab (Moab C2b8 Anti Cd20, Chimeric)
Dosage: 680 mg
Vincristine Sulfate
Dosage: 2.8 mg
Adverse event in 6 year old female receiving Cyclophosphamide
Reported by a physician from United States on 2007-10-30
Patient: 6 year old female
Adverse reactions / side effects: Acute Myeloid Leukaemia, Sepsis, Acute Respiratory Distress Syndrome
Suspect drug(s):
Carboplatin
Indication: Retinoblastoma Bilateral
Cyclophosphamide
Indication: Retinoblastoma Bilateral
Etoposide
Indication: Retinoblastoma Bilateral
Vincristine
Indication: Retinoblastoma Bilateral
Adverse event in male receiving Cyclophosphamide
Reported by a individual with unspecified qualification from United States on 2007-10-30
Patient: male, weighing 97.0 kg (213.4 pounds)
Adverse reactions / side effects: White Blood Cell Count Decreased, Neutropenia
Adverse event resulted in: hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 1650 mg
Doxorubicin Hydrochloride
Dosage: 110 mg
Prednisone TAB
Dosage: 1000 mg
Rituximab (Moab C2b8 Anti Cd20, Chimeric)
Dosage: 800 mg
Vincristine Sulfate
Dosage: 2 mg
Adverse event in 62 year old female receiving Cyclophosphamide
Reported by a individual with unspecified qualification from United Kingdom on 2007-10-30
Patient: 62 year old female
Adverse reactions / side effects: Viral Infection, JC Virus Infection, Muscle Twitching, Progressive Multifocal Leukoencephalopathy
Adverse event resulted in: death, life threatening event
Suspect drug(s):
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2004-02-01
Doxorubicin Hydrochloride
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2004-02-01
Prednisone
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2004-02-01
Rituximab
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2006-02-01
Vincristine
Indication: Chronic Lymphocytic Leukaemia
Start date: 2003-09-01
End date: 2004-02-01
Other drugs received by patient: Chlorambucil; Fludarabine Phosphate
Adverse event in 7 year old female receiving Cyclophosphamide
Reported by a physician from Greece on 2007-10-30
Patient: 7 year old female, weighing 25.0 kg (55.0 pounds)
Adverse reactions / side effects: Parvovirus Infection, Histiocytosis Haematophagic, Drug Interaction, Immunosuppression
Adverse event resulted in: death
Suspect drug(s):
Azathioprine
Indication: Drug USE FOR Unknown Indication
Cyclophosphamide
Dosage: 800 mg iv
Indication: Drug USE FOR Unknown Indication
Start date: 2007-04-27
End date: 2007-04-27
Cyclosporine
Indication: Drug USE FOR Unknown Indication
Start date: 2007-05-02
End date: 2007-05-04
Entanercept
Indication: Drug USE FOR Unknown Indication
Kineret
Dosage: 25 mg/kg once sc
Indication: Vasculitis
Start date: 2006-03-22
End date: 2007-04-20
Methotrexate
Indication: Drug USE FOR Unknown Indication
Methylprednisolone
Dosage: 300 mg/kg iv
Indication: Drug USE FOR Unknown Indication
Start date: 2007-05-03
End date: 2007-05-05
Prednisolone
Indication: Drug USE FOR Unknown Indication
Start date: 2001-06-21
End date: 2002-05-15
Adverse event in female receiving Cyclophosphamide
Reported by a individual with unspecified qualification from Germany on 2007-10-30
Patient: female
Adverse reactions / side effects: Neck Pain, Headache
Adverse event resulted in: hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: daily dose:375mg/m2-freq:once every cycle
Docetaxel
Dosage: daily dose:60mg/m2-freq:once every cycle
Doxorubicin Hydrochloride
Dosage: daily dose:37.5mg/m2-freq:once every cycle
Granisetron HCL
Dosage: daily dose:1mg
Start date: 2007-03-29
End date: 2007-03-29
Neulasta
Dosage: daily dose:6mg-freq:once every cycle
Indication: Chemotherapy
Start date: 2007-03-29
End date: 2007-06-30
Adverse event in female receiving Cyclophosphamide
Reported by a physician from Germany on 2007-10-30
Patient: female, weighing 76.0 kg (167.2 pounds)
Adverse reactions / side effects: Diverticulum Intestinal, Gastritis
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 350 mg, unk
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-28
End date: 2007-02-13
Fludarabine Phosphate
Dosage: 35 mg, unk
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-28
End date: 2007-02-13
Neulasta
Dosage: 6 mg, unk
Indication: Drug USE FOR Unknown Indication
Start date: 2006-10-13
End date: 2007-02-13
Rituximab
Dosage: 880 mg, unk
Indication: Chronic Lymphocytic Leukaemia
Start date: 2006-08-28
End date: 2007-02-13
Uromitexan
Dosage: 100 mg, unk
Indication: Drug USE FOR Unknown Indication
Start date: 2006-08-28
End date: 2007-02-13
Other drugs received by patient: Dexamethasone 0.5mg TAB; Kevatril; Tavegil; Acetaminophen; Prednisolut
Adverse event in 65 year old male receiving Cyclophosphamide
Reported by a physician from United States on 2007-10-29
Patient: 65 year old male
Adverse reactions / side effects: Renal Failure, Transient Ischaemic Attack, Hypertension
Adverse event resulted in: hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 600 mg/m2, unk
Indication: Chronic Lymphocytic Leukaemia
Pentostatin
Dosage: 4 mg/m2, unk
Indication: Chronic Lymphocytic Leukaemia
Rituxan
Dosage: 100 mg, unk
Indication: Chronic Lymphocytic Leukaemia
Other drugs received by patient: Fluids (Unk Ingredients); IV Hydration (Unk Ingredients); Anti Nausea Medicine Unkown Name; Anti Nausea Medicine Unkown Name; Acetaminophen; Diphenhydramine HCL; Allopurinol; Trimethoprim + Sulfamethoxazole; Neupogen
Adverse event in female receiving Cyclophosphamide
Reported by a consumer/non-health professional from United States on 2007-10-29
Patient: female
Adverse reactions / side effects: Respiratory Failure, Pulmonary Fibrosis
Adverse event resulted in: death
Suspect drug(s):
Cyclophosphamide
Indication: Chemotherapy
Doxorubicin HCL
Indication: Chemotherapy
Neulasta
Indication: Prophylactic Chemotherapy
Rituximab
Indication: Chemotherapy
Vincristine Sulfate
Indication: Chemotherapy
Other drugs received by patient: Prednisolone
Adverse event in 72 year old female receiving Cyclophosphamide
Reported by a physician from United States on 2007-10-29
Patient: 72 year old female
Adverse reactions / side effects: Neutropenic Sepsis, Haemolytic Anaemia
Suspect drug(s):
Cyclophosphamide
Dosage: 600 mg/m2, q3w
Indication: Chronic Lymphocytic Leukaemia
Pentostatin
Dosage: 4 mg/m2, q3w
Indication: Chronic Lymphocytic Leukaemia
Rituxan
Dosage: 100 mg, unk
Indication: Chronic Lymphocytic Leukaemia
Rituxan
Dosage: 375 mg/m2, unk
Other drugs received by patient: Hydration (Unk Ingredients)
Adverse event in female receiving Cyclophosphamide
Reported by a individual with unspecified qualification from United States on 2007-10-29
Patient: female, weighing 56.1 kg (123.4 pounds)
Adverse reactions / side effects: Lymphopenia, Neutropenia, Leukopenia
Suspect drug(s):
Cyclophosphamide
Dosage: 960 mg
Doxorubicin Hydrochloride
Dosage: 50 mg
Adverse event in 46 year old female receiving Cyclophosphamide
Reported by a individual with unspecified qualification from Japan on 2007-10-29
Patient: 46 year old female
Adverse reactions / side effects: Cytomegalovirus Antigen Positive, Haptoglobin Decreased, RED Blood Cell Abnormality, Proteinuria, Blood Lactate Dehydrogenase Increased, Thrombotic Microangiopathy, Focal Glomerulosclerosis
Adverse event resulted in: disablity
Suspect drug(s):
Cyclophosphamide
Neoral
Dosage: unk, unk
Administration route: Oral
Indication: Allogenic Bone Marrow Transplantation Therapy
End date: 2007-03-22
Sandimmune
Dosage: 3 mg/kg/day
Indication: Allogenic Bone Marrow Transplantation Therapy
Start date: 2006-12-12
Other drugs received by patient: Methotrexate; Campath; Fludarabine Phosphate
Adverse event in 75 year old male receiving Cyclophosphamide
Reported by a individual with unspecified qualification from Japan on 2007-10-29
Patient: 75 year old male
Adverse reactions / side effects: Nutritional Condition Abnormal, Pneumonia Aspiration, Rectal Haemorrhage, Clostridium Difficile Colitis, Melaena
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Adriamycin PFS
Indication: Leukaemia Plasmacytic
Cyclophosphamide
Indication: Leukaemia Plasmacytic
Dexamethasone 0.5mg TAB
Indication: Leukaemia Plasmacytic
Melphalan
Indication: Leukaemia Plasmacytic
Prednisone
Indication: Leukaemia Plasmacytic
Vincristine
Indication: Leukaemia Plasmacytic
Adverse event in receiving Cyclophosphamide
Reported by a physician from Italy on 2007-10-29
Patient:
Adverse reactions / side effects: JC Virus Infection, Progressive Multifocal Leukoencephalopathy
Adverse event resulted in: death
Suspect drug(s):
Cyclophosphamide
Dosage: 7 g/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Cytarabine
Dosage: 2 g/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 75 mg/m2, x2
Rituxan
Dosage: 375 mg/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
|
